«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2021年03期

页码:

272-276

栏目:

论著

出版日期:

2021-06-20

文章信息/Info

Title:

Clinical effect of noninvasive ventilator in the treatment of chronic obstructive pulmonary disease with acute exacerbation and type Ⅱ respiratory failure

作者:

杨静翔¹; 秦光梅¹; 罗虎²

402460 重庆,重庆医科大学附属永川医院呼吸与危重症医学科¹ 400038 重庆,陆军(第三)军医大学第一附属医院呼吸与危重症医学科²

Author(s):

Yang Jingxiang¹;  Qin Guangmei¹;  Luo Hu².

¹Department of Respiratory and Critical Care Medicine, Yongchuan Hospital, Chongqing Medical University, Chongqing 402460, China; ²Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Army Military Medical University, Chongqing 400038, China

关键词:

肺疾病; 慢性阻塞性;  Ⅱ型呼吸衰竭;  无创机械通气

Keywords:

Chronic obstructive pulmonary disease;  Type Ⅱ respiratory failure;  Noninvasive mechanical ventilation

分类号:

R563

DOI:

10.3877/cma.j.issn.1674-6902.2021.03.002

摘要:

目的 评价双水平气道正压(BiPAP)无创机械通气治疗慢性阻塞性肺疾病急性加重期(AECOPD)合并Ⅱ型呼吸衰竭患者的临床疗效及其安全性。方法 回顾我院呼吸内科2015年1月至2018年6月住院治疗的378例AECOPD合并Ⅱ型呼吸衰竭患者的临床资料,根据治疗方式分为观察组198例和对照组180例。对照组采用常规治疗,观察组在对照组治疗基础上接受经口鼻面罩BiPAP无创机械通气。记录治疗前、治疗2 h、治疗后24 h的血气分析指标、临床缓解情况以及不良反应发生情况,并比较组间差异。结果 治疗2 h后,观察组患者pH、氧合指数(PaO₂/FiO₂)、动脉血氧分压(PaO₂)、乳酸水平改善显著(P<0.05),对照组无显著改善(P>0.05)。治疗24 h后,两组患者pH、PaO₂/FiO₂、PaO₂、乳酸水平均显著改善,且观察组患者比对照组患者改善更显著(P<0.05)。两组患者治疗后3 d临床缓解率无显著差异(χ²=1.042,P=0.307),治疗后5 d、7 d观察组患者临床缓解率均明显高于对照组(P<0.05)。两组患者胃胀气、口咽溃疡、口腔真菌发生率均无显著差异(P>0.05),观察组肺性脑病发生率(3.03% vs. 10.0%,P=0.006)及气管插管率(7.57% vs. 11.11%,P=0.033)均明显低于对照组; 无创通气合理使用可有效降低患者的平均住院日和医疗费用。结论 经口鼻面罩 BiPAP无创机械通气是治疗AECOPD合并Ⅱ型呼吸衰竭的一种有效安全的治疗手段。

Abstract:

Objective To evaluate the clinical efficacy and safety of bi-level positive airway pressure(BiPAP)noninvasive mechanical ventilation in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)combined with type Ⅱ respiratory failure. Methods The clinical data of 378 patients with AECOPD combined with type Ⅱ respiratory failure who were hospitalized from January 2015 to June 2018 in our Department of Respiratory Medicine were reviewed. They were divided into observation group 198 cases and control group 180 cases according to treatment methods. The control group received conventional treatment, and the observation group received non-invasive mechanical ventilation with oral nasal mask BiPAP based on the treatment of the control group. Blood gas analysis indicators, clinical remissions, and adverse reactions were recorded before treatment, 2 hours, and 24 hours after treatment, and the differences between groups were compared. Results After 2 hours of treatment, the patients in the observation group had significant improvements in pH, oxygenation index(PaO₂/FiO₂), PaO₂, and lactic acid levels(P<0.05), while the control group had no significant improvement(P>0.05). After 24 hours of treatment, the pH, PaO₂/FiO₂, PaO₂, and lactic acid levels of the two groups of patients improved significantly, and the patients in the observation group improved more significantly than those in the control group(P<0.05). There was no significant difference in the clinical response rate between the two groups after 3 days of treatment(χ²=1.042, P=0.307). The clinical response rate of the observation group was significantly higher than that of the control group at 5 and 7 days after treatment(P<0.05). There was no significant difference in the incidence of flatulence, oropharyngeal ulcers, and oral fungi in the two groups(P>0.05). The incidence of pulmonary encephalopathy(3.03% vs. 10.0%, P=0.006)and tracheal intubation rate(7.57% vs. 11.11%, P=0.033)in the observation group were significantly lower than those in the control group; the reasonable use of noninvasive ventilator can effectively reduce the average hospitalization day and medical expenses of patients. Conclusion Oral and nasal mask BiPAP noninvasive mechanical ventilation is an effective treatment for AECOPD combined with type Ⅱ respiratory failure, and it is worthy of clinical application.

参考文献/References:

1 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2 Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD Executive Summary[J]. Arch Bronconeumol, 2017, 53(3): 128-149.
3 Myers LC, Faridi MK, Currier P, et al. ICU Utilization for patients with acute exacerbation of chronic obstructive pulmonary disease receiving noninvasive ventilation[J]. Critical care medicine, 2019, 47(5): 677-684.
4 Wang J, Cui Z, Liu S, et al. Early use of noninvasive techniques for clearing respiratory secretions during noninvasive positive-pressure ventilation in patients with acute exacerbation of chronic obstructive pulmonary disease and hypercapnic encephalopathy: A prospective cohort study [J]. Medicine, 2017, 96(12): e6371.
5 刘 烨, 代 冰, 苏 佳, 等. 家庭无创通气对重度慢性阻塞性肺疾病稳定期患者疗效的荟萃分析[J]. 中华结核和呼吸杂志, 2017, 40(5): 354-362.
6 Dave S. Pharmacological treatment for COPD; GOLD 2017 changes direction[J]. Br J Clin Pharmacol, 2017, 83(5): 935-937.
7 Hillman DR, Jungquist CR, Auckley D. Perioperative implementation of noninvasive positive airway pressure therapies[J]. Respir Care, 2018, 63(4): 479-487.
8 陈云坤, 冯英凯. GOLD 2017新版指南要点解读[J]. 现代医药卫生, 2017,(4): 481-483.
9 Ojo O, Lagan AL, Rajendran V, et al. Pathological changes in the COPD lung mesenchyme-Novel lessons learned from in vitro and in vivo studies[J]. Pulm Pharmacol Ther, 2014, 29(2): 121-128.
10 王慧杰, 徐武成, 黄华琼. 慢性阻塞性肺疾病急性加重期炎性生物标志物研究进展[J]. 国际呼吸杂志, 2019, 39(2): 134-138.
11 Wong EKC, Lee P, Ansary S, et al. Role of venous blood gases in hypercapnic respiratory failure chronic obstructive pulmonary disease patients presenting to the emergency department[J]. Intern Med J, 2019, 49(7): 834-837.
12 Seiler F, Trudzinski FC, Kredel M, et al. Update: acute hypercapnic respiratory failure[J]. Med Klin Intensivmed Notfmed, 2019, 114(3): 234-239.
13 Osadnik CR, Tee VS, Carson-Chahhoud KV, et al. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease: a Cochrane review update[J]. Cochrane Database Syst Rev, 2017, 7(7): CD004104.
14 Zhang J, Wang Y, Cao J, et al. Noninvasive ventilation with complex critical care ventilator in the treatment of acute exacerbation of chronic obstructive pulmonary disease[J]. J Int Med Res, 2014, 42(5): 1102-1109.
15 Pejkovska S, Kaeva BJ, Goseva Z, et al. Predictive factors for the effect of treatment by noninvasive ventilation in patients with respiratory failure as a result of acute exacerbation of the chronic obstructive pulmonary disease[J]. Open Access Maced J Med Sci, 2015, 3(4): 655-660.
16 Peng L, Ren PW, Liu XT, et al. Use of noninvasive ventilation at the pulmonary infection control window for acute respiratory failure in AECOPD patients[J]. Medicine(Baltimore), 2016, 95(24): e3880.
17 Burns KE, Meade MO, Premji A, et al. Noninvasive positive-pressure ventilation as a weaning strategy for intubated adults with respiratory failure[J]. Cochrane Database Syst Rev, 2013, 2013(12): CD004127.
18 Wang L, Li X, Yang Z, et al. Semi-recumbent position versus supine position for the prevention of ventilator-associated pneumonia in adults requiring mechanical ventilation[J]. Cochrane Database Syst Rev, 2016, 2016(1): CD009946.
19 Lv Y, Lv Q, Lv Q, et al. Pulmonary infection control window as a switching point for sequential ventilation in the treatment of COPD patients: a meta-analysis[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12: 1255-1267.
20 Hua F, Xie H, Worthington HV, et al. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia[J]. Cochrane Database Syst Rev, 2016, 10(10): CD008367.
21 Gao E, Zhang C, Wang J. Effects of budesonide combined with noninvasive ventilation on PCT, sTREM-1, chest lung compliance, humoral immune function and quality of life in patients with AECOPD complicated with type Ⅱ respiratory failure[J]. Open Med(Wars), 2019, 14: 271-278.
22 慢性阻塞性肺疾病急性加重诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2014年修订版)[J]. 国际呼吸杂志, 34(1): 1-11.
23 王 蕾, 杨 汀, 王 辰. 2017年版慢性阻塞性肺疾病诊断、处理和预防全球策略解读[J]. 中国临床医生杂志, 2017, 45(1): 104-108.
24 张叶钦, 胡晓芸, 侯飞飞, 等. 早期慢性阻塞性肺疾病诊治进展[J]. 临床肺科杂志, 2018, 23(3): 547-550.
25 赵汉卓. 睡眠呼吸暂停低通气综合征给予BiPAP无创呼吸机治疗的临床分析[J]. 临床医药文献电子杂志, 2018, 5(63): 53-54.
26 孙贤辉, 谭成燕. 无创呼吸机治疗慢性阻塞性肺疾病急性加重合并Ⅱ型呼吸衰竭30例临床分析[J]. 中国医疗器械信息, 2018, 24(18): 97-98.
27 罗亚艳. BiPAP无创呼吸机联合尼可刹米治疗AECOPD合并Ⅱ型呼吸衰竭重度高碳酸血症的临床研究[J]. 基层医学论坛, 2018, 22(13): 1858-1859.
28 王 永, 刘亚玲, 刘大凤, 等. 双水平气道正压无创呼吸机联合尼可刹米治疗急性加重期慢性阻塞性肺病合并Ⅱ型呼吸衰竭患者的临床疗效[J]. 实用医院临床杂志, 2020, 17(4): 31-34.
29 苏 宏, 梁晓海, 刘 慧, 等. BiPAP无创呼吸机联合尼可刹米治疗AECOPD合并Ⅱ型呼吸衰竭、重度高碳酸血症的临床研究[J]. 中国医药导报, 2015, 12(23): 121-124.
30 何 会, 李荆萍. BiPAP无创呼吸机联合呼吸兴奋剂治疗AECOPD合并Ⅱ型呼吸衰竭效果观察[J]. 中外医学研究, 2018, 16(7): 140-141.
31 林育珠, 萧锦联, 祝日华, 等. 纳洛酮联合无创呼吸机对COPD 并呼吸衰竭老年患者疗效影响[J]. 中国现代药物应用, 2020, 14(17): 158-160.
32 周若兰. 纳洛酮联合无创呼吸机在老年慢性阻塞性肺疾病合并呼吸衰竭中的临床疗效[J]. 当代医学, 2020, 26(29): 65-68.
33 曹 炯. 体外膈肌起搏联合祛痰药物治疗慢性阻塞性肺疾病患者疗效观察[J]. 医药前沿, 2018, 8(17): 104-105.

备注/Memo

备注/Memo:

基金项目: 国家自然科学基金青年基金项目(81700293)重庆市科卫联合医学科研项目(2020FYYX012)
通信作者: 罗 虎, Email: luohucy@163.com

常用功能

更新日期/Last Update: 2021-06-20